{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Pill&page=34",
    "query": {
      "intervention": "Study Pill",
      "page": 34
    },
    "page_size": 10
  },
  "pagination": {
    "page": 34,
    "page_size": 10,
    "total_count": 1391,
    "total_pages": 140,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Pill&page=35&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Pill&page=33&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T01:18:10.106Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00763867",
      "title": "Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Sildenafil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 216,
      "start_date": "2008-09",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2014-07-23",
      "last_synced_at": "2026-11-03T01:18:10.106Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00763867"
    },
    {
      "nct_id": "NCT05345457",
      "title": "Outpatient Antibiotics Following Previable Rupture of Membranes (pPPROM) Between 18 0/7 and 22 6/7 Weeks Gestational Age",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pregnancy Preterm",
        "Pregnancy Prom",
        "PROM, Preterm (Pregnancy)",
        "PROM (Pregnancy)",
        "Premat Rupture Membranes Preterm Unspec to Length of Time Between Rupture/Labor",
        "Premature Birth"
      ],
      "interventions": [
        {
          "name": "Azithromycin Pill",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin Pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University Hospitals Cleveland Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1,
      "start_date": "2023-01-13",
      "completion_date": "2024-02-26",
      "has_results": true,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-11-03T01:18:10.106Z",
      "location_count": 3,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05345457"
    },
    {
      "nct_id": "NCT03418675",
      "title": "Brexpiprazole in Borderline Personality Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Borderline Personality Disorder"
      ],
      "interventions": [
        {
          "name": "Rexulti",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 80,
      "start_date": "2018-11-26",
      "completion_date": "2021-04-14",
      "has_results": true,
      "last_update_posted_date": "2022-03-18",
      "last_synced_at": "2026-11-03T01:18:10.106Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03418675"
    },
    {
      "nct_id": "NCT04934228",
      "title": "Mitigating the Pro-inflammatory Phenotype of Obesity",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Blood Pressure",
        "Diabetes",
        "Obesity",
        "Insulin Resistance",
        "Diuretics Drug Reactions",
        "Sympathetic Nerve Activity"
      ],
      "interventions": [
        {
          "name": "Hydrochlorothiazide 12.5Mg Tab",
          "type": "DRUG"
        },
        {
          "name": "Clonidine Pill",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 60,
      "start_date": "2021-07-01",
      "completion_date": "2027-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-11-03T01:18:10.106Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04934228"
    },
    {
      "nct_id": "NCT01053156",
      "title": "Trial of Minocycline to Treat Children With Fragile X Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fragile X Syndrome"
      ],
      "interventions": [
        {
          "name": "minocycline hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "42 Months",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "42 Months to 16 Years"
      },
      "enrollment_count": 66,
      "start_date": "2010-01",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-11-03T01:18:10.106Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01053156"
    },
    {
      "nct_id": "NCT02822937",
      "title": "Sensitivity of Project: EVO Monitor Cognitive Measurements to Pharmacological Agents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Methylphenidate",
          "type": "DRUG"
        },
        {
          "name": "Triazolam",
          "type": "DRUG"
        },
        {
          "name": "Project: EVO",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Akili Interactive Labs, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "40 Years to 55 Years"
      },
      "enrollment_count": 18,
      "start_date": "2016-07",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2016-11-07",
      "last_synced_at": "2026-11-03T01:18:10.106Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02822937"
    },
    {
      "nct_id": "NCT02865629",
      "title": "N-acetylcysteine in the Treatment of Depressive Symptoms in Bipolar Offspring",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "N-acetyl cysteine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "15 Years to 24 Years"
      },
      "enrollment_count": 22,
      "start_date": "2016-08",
      "completion_date": "2019-09",
      "has_results": false,
      "last_update_posted_date": "2018-05-14",
      "last_synced_at": "2026-11-03T01:18:10.106Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02865629"
    },
    {
      "nct_id": "NCT05276492",
      "title": "Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostate Adenocarcinoma",
        "Prostate Neoplasm",
        "Prostate Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "Abiraterone Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Prednisone tablet",
          "type": "DRUG"
        },
        {
          "name": "Drug Dairy/Log",
          "type": "OTHER"
        },
        {
          "name": "Low-fat meal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2023-01-24",
      "completion_date": "2024-11-16",
      "has_results": false,
      "last_update_posted_date": "2025-10-03",
      "last_synced_at": "2026-11-03T01:18:10.106Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05276492"
    },
    {
      "nct_id": "NCT01605539",
      "title": "Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Opiate Addiction"
      ],
      "interventions": [
        {
          "name": "Cannabidiol 400",
          "type": "DRUG"
        },
        {
          "name": "Cannabidiol 800",
          "type": "DRUG"
        },
        {
          "name": "Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hurd,Yasmin, Ph.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2012-05",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2020-08-11",
      "last_synced_at": "2026-11-03T01:18:10.106Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01605539"
    },
    {
      "nct_id": "NCT00728000",
      "title": "Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2008-08",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2019-11-25",
      "last_synced_at": "2026-11-03T01:18:10.106Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00728000"
    }
  ]
}